Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
Become a Member | Sign in
Home>News>This Article

Sartorius Stedim Announces Offer to Acquire TAP Biosystems

Published: Tuesday, October 08, 2013
Last Updated: Tuesday, October 08, 2013
Bookmark and Share
Sartorius Stedim Biotech to further expand its portfolio of single-use fermentors.

Sartorius Stedim Biotech has made a cash offer to acquire the UK company TAP Biosystems Group plc (TAP Biosystems) through its wholly owned subsidiary Sartorius Stedim Biotech GmbH.

The proposed transaction, which is subject to customary closing conditions, including the approval of TAP’s shareholders, values the equity of TAP Biosystems at approximately €33 million.

The transaction has been unanimously approved by the boards of directors of both companies and is expected to close at the end of 2013.

In making the announcement, Joachim Kreuzburg, the Chief Executive of Sartorius Stedim Biotech, stated, “TAP Biosystems’ fermentors are a great fit extending our reach into the small scale cell culture applications. Adding capabilities in the early steps of upstream bioprocessing will enable us to provide our biopharma customers highly effective and scalable solutions to accelerate cell line selection, speed-up process development and ultimately help them bringing their biologics to market faster”.

TAP Biosystems plc specializes in the design and development of small-scale, multi-parallel fermentation systems particularly for biopharmaceutical applications.

With its ambr®-product family, the company has launched a novel platform technology for single-use fermentation that is designed to mimic mammalian cell culture at small scale, a highly innovative alternative to conventional systems.

Furthermore TAP Biosystem’s portfolio includes automated cell processing systems and other bench top equipment.

Founded in 1987, the company is headquartered in Royston, UK, and has a sales and support facility near Wilmington, Delaware, USA. TAP Biosystems generated sales revenue of approx. €26 million in 2012/13 and employs about 160 people worldwide.

Welcoming the acquisition, David Newble, CEO of TAP Biosystems, said, “As a market leader in bioprocessing technologies with a strong position in fermentation, Sartorius Stedim Biotech is well-placed to maximize the opportunities of our novel, highly innovative cell culture technologies. We look forward to joining such a well-recognized organization as Sartorius Stedim that will enable us to grow our business further with a wealth of complementary technologies and products”.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sartorius Stedim Biotech and GE Healthcare Sign Worldwide OEM Supply Agreement
Expands GE’s start-to-finish offering for cost efficient manufacture of biopharmaceuticals.
Tuesday, September 01, 2015
Scientific News
Robotic Cleaning Technique Could Automate Neuroscience Research
New robotic cleaning technique allows pipettes used in patch-clamping to be re-used up to 11 or more times.
Study Implicates Glial Cells in Fragile X Syndrome
The genetic defect behind a common cause of mental retardation affects not only neurons but also the more numerous glial cells in the brain.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
A Step Forward in Building Functional Human Tissues
Researchers at Wyss Institute have bioprinted a tubular 3D renal architecture that recapitulates functions of the kidney.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Curcumin Shows Promise as Cancer Treatment
When delivered at the correct circadian phase, curcumin demonstrates sustained toxicity in cancer cells and should be considered for use in patient care.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Uncovering Water Bear Resilience
A protein identified in water bears can protect DNA of human cells from lethal doses of radiation damage.
Using Stem Cells to Grow a 3D Lung-in-a-Dish
Researchers have created 3D lung-like tissue from lung-derived stem cells. The tissue can be used to study lung diseases.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos